<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766346</url>
  </required_header>
  <id_info>
    <org_study_id>20.09.INF</org_study_id>
    <nct_id>NCT04766346</nct_id>
  </id_info>
  <brief_title>Nutritional Supplementation in Children Aged 1-3 Years Experiencing Growth Concerns</brief_title>
  <official_title>Nutritional Supplementation in Children Aged 1-3 Years Experiencing Growth Concerns: a Prospective, Single-arm, Open-label, Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label clinical trial will gain evidence of the effect of an oral Nutritional&#xD;
      Supplement (NS) to help improve catch-up growth and support learning skills in children with&#xD;
      growth concerns.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this clinical trial is to to assess the effect of NS on weight gain and linear growth.</measure>
    <time_frame>Day 1 to Day 113</time_frame>
    <description>The primary endpoint is the change in weight-for-length/height z-score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 64, Day 85, Day 113</time_frame>
    <description>Measurement of Weight in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length/height</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 64, Day 85, Day 113</time_frame>
    <description>Measurement of length/height in cms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triceps skin fold thickness</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 64, Day 85, Day 113</time_frame>
    <description>Measurement of triceps skinfold thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-scapular skinfold thickness</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 64, Day 85, Day 113</time_frame>
    <description>Measurement of sub-scapular skinfold thickness in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suprailiac skinfold thickness</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 64, Day 85, Day 113</time_frame>
    <description>Measurement of suprailiac skinfold thickness in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 64, Day 85, Day 113</time_frame>
    <description>BMI will be calculated and expressed in Kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Z scores and percentiles</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 64, Day 85, Day 113</time_frame>
    <description>1) Sex-age-specific weight, length/height, BMI and triceps and subscapular skinfold thickness percentiles and Z-scores calculated according to WHO standards. 2) Changes from baseline in sex-age-specific percentiles and Z-scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrient intake</measure>
    <time_frame>Day 22, Day 43, Day 113</time_frame>
    <description>Nutrient intake from 3-day Food Intake Diaries that will be completed at home for two weekdays and 1 weekend day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Learning skills</measure>
    <time_frame>Day 1, Day 113</time_frame>
    <description>Learning Scores derived from the Ages and Stages Questionnaire, Third Edition (ASQ-3) (with a focus on communication and problem-solving skills)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperament and behavior</measure>
    <time_frame>Day 1, Day 113</time_frame>
    <description>Temperament and behaviour scores from the Early Childhood Behavior Questionnaire- Short Form (ECBQ-SF) completed. The ECBQ-SF has 107 questions and assesses dimensions of temperament such as activity Level/Energy, attentional Focusing, attentional Shifting, cuddliness, discomfort, fear, frustration, high-intensity Pleasure, impulsivity, inhibitory Control, low-intensity Pleasure, motor Activation, perceptual Sensitivity, positive Anticipation, sadness, shyness, sociability and soothability.The scale items ask parents to report on the frequency of specific behaviours in frequently occurring contexts on a 7 point likert scale ranging from never to always.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child and parent well-being reported from the parents' perspective</measure>
    <time_frame>Day 1, Day 113</time_frame>
    <description>Child health-related quality of life scores assessed using the Infant and Toddler Quality of Life Questionnaire Short Form (ITQOL-SF47). The ITQOL-SF47 has 47 questions and assesses domains such as the overall health, physical abilities, growth and development, bodily pain/discomfort, temperament and moods, general health perceptions, parent impact - emotional, parent impact - time and family cohesion with a score of 0 (worst) to 100 (best) for each of these domains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product acceptance</measure>
    <time_frame>Day 22, Day 64, Day 113</time_frame>
    <description>Product acceptance scores from the Toddler Milk Satisfaction Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product acceptance including child-liking and post-ingestive effects</measure>
    <time_frame>Day 22, Day 64, Day 113</time_frame>
    <description>Primary facial expression valence and child heart rate variability derived from the ANURA for Research (smartphone app) while child is consuming one serving of the NS</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessment</measure>
    <time_frame>Day -7 to Day 113 + 30</time_frame>
    <description>Data from standard AE reporting (including common illnesses) for safety assessment from date of ICF signing through 30 days after the last day of NS intake.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sick days</measure>
    <time_frame>Day -7 to Day 113 + 30</time_frame>
    <description>Total number of sick days</description>
  </other_outcome>
  <other_outcome>
    <measure>Concomittant medications and treatment</measure>
    <time_frame>Day -7 to Day 113 + 30</time_frame>
    <description>All concomitant medications / treatments used to treat illnesses and other conditions will be recorded (both dose and duration) through 30 days after the last day of NS intake.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Growth</condition>
  <condition>Learning</condition>
  <condition>Toddlers</condition>
  <arm_group>
    <arm_group_label>Nutritional Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The NS is a fortified cow's milk-based product provided in powdered form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fortified Cow's Milk-Based Oral Nutritional Supplement</intervention_name>
    <description>The NS is a fortified cow's milk-based product provided in powdered form that provides the appropriate amount of energy and protein to promote growth in children.</description>
    <arm_group_label>Nutritional Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the child's parent(s) / legally acceptable representative (LAR) has been informed of&#xD;
             all pertinent aspects of the study.&#xD;
&#xD;
          2. Child was full-term at birth (i.e., ≥ 37 completed weeks of gestation with a birth&#xD;
             weight of ≥ 2.5 kg and ≤ 4.5 kg).&#xD;
&#xD;
          3. Child is age 12 - 36 months and generally healthy (acute illness in a minor condition&#xD;
             which are common in childhood such as viral or bacterial infection e.g.&#xD;
             conjunctivitis, otitis media, upper/lower respiratory tract infection,&#xD;
             gastroenteritis, hand foot &amp; mouth disease at time of enrolment is permitted).&#xD;
&#xD;
          4. Children whose parents show some concern about their child's growth, such as child is&#xD;
             too thin for his or her length/height, child has experienced recent rapid weight loss&#xD;
             or failure to gain weight or length/height, or child's growth curve shows a downward&#xD;
             trajectory of growth velocity&#xD;
&#xD;
          5. Child has a weight-for-length/height ≤ 25th percentile as per WHO growth charts.&#xD;
&#xD;
          6. Parents agree to feed their child a nutritional supplement in addition to normal diet.&#xD;
&#xD;
          7. Child's parent(s) / guardian can be contacted directly by telephone or email&#xD;
             throughout the study.&#xD;
&#xD;
          8. Child's parent is of legal age of consent, must understand the informed consent form&#xD;
             and other study documents, and is willing and able to fulfill the requirements of the&#xD;
             study protocol.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Child is currently breastfed or is consuming breast milk&#xD;
&#xD;
          2. Child has known or suspected cows' milk protein intolerance / allergy, lactose&#xD;
             intolerance, soy intolerance / allergy, fish oil intolerance / allergy, or other food&#xD;
             allergies that impact diet.&#xD;
&#xD;
          3. Child fed vegan, vegetarian, or vegetarian plus fish diets in which milk products are&#xD;
             excluded&#xD;
&#xD;
          4. Child has chronic illness or other disease including any condition that impacts&#xD;
             feeding or growth&#xD;
&#xD;
          5. Child having any congenital malformation (e.g., gastrointestinal tract atresia) or&#xD;
             surgery sequelae (e.g., short bowel syndrome) potentially affecting feeding or growth&#xD;
&#xD;
          6. Child has been diagnosed with Infantile anorexia nervosa&#xD;
&#xD;
          7. Child has other medical or psychiatric condition that, in the judgement of the&#xD;
             investigator, would make the child inappropriate for entry into the study.&#xD;
&#xD;
          8. Child or child's parent(s) not willing and/or not able to comply with scheduled visits&#xD;
             and the requirements of the study protocol.&#xD;
&#xD;
          9. Child of any investigational site staff member or Nestlé employee directly involved in&#xD;
             the conduct of the trial.&#xD;
&#xD;
         10. Child is currently participating in or has participated in another clinical trial&#xD;
             within 4 weeks prior to enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elvira M. Estorninos, MD</last_name>
    <phone>+632 8825 5236</phone>
    <phone_ext>444</phone_ext>
    <email>elvie_323@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Las Piñas Doctors Hospital</name>
      <address>
        <city>Las Piñas</city>
        <zip>1742</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira M. Estorninos, MD</last_name>
      <phone>+632 8825 5236</phone>
      <phone_ext>444</phone_ext>
      <email>elvie_323@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Elvira M. Estorninos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

